ArticleExploratory research in clinical and social pharmacy2026
Potential clinical impact of pharmaceutical interventions in an interprofessional medication management program.
Article in Exploratory research in clinical and social pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Medication reviews (MR) can improve medication safety, especially when followed by continuous medication management (MM). The interprofessional MM program ARMIN resulted in a significantly reduced mortality risk. To gain a deeper understanding of what contributed to this effect, we aimed to investigate the pharmaceutical interventions (PI) conducted by the community pharmacies and their communication with the physicians. Methods: We conducted an intervention study in the ambulatory setting with a pre-post design and an observational period of approximately 6 months per patient to assess (1) number and types of drug-related problems (DRP) identified and solved, (2) to evaluate PIs conducted, (3) changes in the medication, (4) clinical and economic impact of the PIs, and (5) involvement of the physicians with respect to type and relevance of DRPs. Results: 79 patients received 10.2 drugs at baseline (median: 9, range 5-26). (1) 420 DRPs were detected during the initial MR and 50 DRPs during MM. (2) 538 PIs were conducted. (3) Changes in the medication were observed in all patients. (4) 404 PIs (76.0%) were classified as successfully implemented. Of these, 84.2% had minor and 12.6% moderate clinical impact. Most of the PIs (81.9%) had no effect on costs. (5) In 42.2% ( Conclusion: Within ARMIN it was possible to solve DRPs with PIs resulting in changes in medication and having a potential clinical impact. The implementation rate shows that intensive collaboration with clear responsibilities between CP and physician is crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.